Product: VeriStrat
-
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
-
Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: A Randomized, Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic Signatures
-
Precision Medicine: Estimated Clinical and Economic Outcomes of Using a Predictive and Prognostic Biomarker to Avoid Ineffective Therapies in Advanced Non-Small Cell Lung Cancer
-
The serum-based VeriStrat test is associated with proinflammatory reactants and clinical outcomes in non-small cell lung cancer patients
-
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
-
The Role Of Proteomic Testing in Improving Prognosis and Care Planning Quality Measures for Lung Cancer
-
INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient management in early and locally advanced NSCLC
-
Predicting clinical outcomes using proteomics in non-small cell lung cancer – The past, present, and future
-
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat® Good versus VeriStrat® Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
-
Precision Medicine: Estimated Clinical and Economic Outcomes of Using a Predictive and Prognostic Biomarker to Avoid Ineffective Therapies in Advanced Non-Small Cell Lung Cancer.